These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15016350)

  • 21. LcrV mutants that abolish Yersinia type III injectisome function.
    Ligtenberg KG; Miller NC; Mitchell A; Plano GV; Schneewind O
    J Bacteriol; 2013 Feb; 195(4):777-87. PubMed ID: 23222719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yersinia pestis LcrV forms a stable complex with LcrG and may have a secretion-related regulatory role in the low-Ca2+ response.
    Nilles ML; Williams AW; Skrzypek E; Straley SC
    J Bacteriol; 1997 Feb; 179(4):1307-16. PubMed ID: 9023216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LcrG-LcrV interaction is required for control of Yops secretion in Yersinia pestis.
    Matson JS; Nilles ML
    J Bacteriol; 2001 Sep; 183(17):5082-91. PubMed ID: 11489861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LcrV of Yersinia pestis enters infected eukaryotic cells by a virulence plasmid-independent mechanism.
    Fields KA; Straley SC
    Infect Immun; 1999 Sep; 67(9):4801-13. PubMed ID: 10456934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of outer membrane proteins of Yersinia pestis and Yersinia pseudotuberculosis strains isolated from India.
    Khushiramani R; Tuteja U; Shukla J; Batra HV
    Indian J Exp Biol; 2004 May; 42(5):508-14. PubMed ID: 15233478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FPR1 is the plague receptor on host immune cells.
    Osei-Owusu P; Charlton TM; Kim HK; Missiakas D; Schneewind O
    Nature; 2019 Oct; 574(7776):57-62. PubMed ID: 31534221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.
    Tinker JK; Davis CT; Arlian BM
    Protein Expr Purif; 2010 Nov; 74(1):16-23. PubMed ID: 20438844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles of YopN, LcrG and LcrV in controlling Yops secretion by Yersinia pestis.
    Hamad MA; Nilles ML
    Adv Exp Med Biol; 2007; 603():225-34. PubMed ID: 17966419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunobiological properties of Yersinia pestis antigens].
    Byvalov AA; Ovodov IuS
    Bioorg Khim; 2011; 37(4):452-63. PubMed ID: 22096987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor.
    Abramov VM; Khlebnikov VS; Vasiliev AM; Kosarev IV; Vasilenko RN; Kulikova NL; Khodyakova AV; Evstigneev VI; Uversky VN; Motin VL; Smirnov GB; Brubaker RR
    J Proteome Res; 2007 Jun; 6(6):2222-31. PubMed ID: 17441749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic analysis of virulence determinants unique to Yersinia pestis.
    Du Y; Galyov E; Forsberg A
    Contrib Microbiol Immunol; 1995; 13():321-4. PubMed ID: 8833863
    [No Abstract]   [Full Text] [Related]  

  • 33. Systematic analysis, identification, and use of CRISPR/Cas13a-associated crRNAs for sensitive and specific detection of the lcrV gene of Yersinia pestis.
    Schultzhaus Z; Wang Z; Stenger D
    Diagn Microbiol Infect Dis; 2021 Mar; 99(3):115275. PubMed ID: 33360431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cloning and expression of Yersinia pestis V antigen in Escherichia coli BL21 (DE3)].
    Fu L; Wang B; Li Q; Lei Q; Jiang L; Shen X
    Wei Sheng Wu Xue Bao; 2003 Aug; 43(4):430-3. PubMed ID: 16276915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague.
    Leary SE; Eley SM; Williamson ED; Titball RW
    Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838
    [No Abstract]   [Full Text] [Related]  

  • 36. A therapeutic strategy against the shared virulence mechanism utilized by both Yersinia pestis and Pseudomonas aeruginosa.
    Sawa T; Wiener-Kronish JP
    Anesthesiol Clin North Am; 2004 Sep; 22(3):591-606, viii-ix. PubMed ID: 15325721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between Yersinia pestis V-antigen (LcrV) and human Toll-like receptor 2 (TLR2) in a modelled protein complex and potential mechanistic insights.
    Wei T; Gong J; Qu G; Wang M; Xu H
    BMC Immunol; 2019 Dec; 20(1):48. PubMed ID: 31842739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis.
    Gébus C; Faudry E; Bohn YS; Elsen S; Attree I
    J Biol Chem; 2008 Aug; 283(35):23940-9. PubMed ID: 18583342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
    Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
    Vaccine; 2008 Nov; 26(50):6329-37. PubMed ID: 18832004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.
    Hill J; Leary S; Smither S; Best A; Pettersson J; Forsberg A; Lingard B; Lipka A; Brown KA; Williamson ED; Titball RW
    Vaccine; 2009 Nov; 27(50):7073-9. PubMed ID: 19786138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.